How to Help Your Patients Find Sandostatin in Stock: A Provider's Guide

When your patient calls your office because they can't find Sandostatin anywhere, the clock is already ticking. For patients managing acromegaly, carcinoid syndrome, or neuroendocrine tumors, missing a monthly octreotide injection can rapidly trigger symptom recurrence and clinical complications.

This guide gives you concrete tools and workflows so your team can respond efficiently — minimizing disruption to your patients' care and reducing the burden on your office staff.

Step 1: Understand the Current Supply Landscape

In 2026, octreotide supply is improving but remains uneven. Before telling a patient "we'll figure it out," it helps to know what you're working with:

• Sandostatin LAR Depot (Novartis): Available through specialty pharmacies but on periodic allocation. Availability varies significantly by region and distribution channel.
• Generic octreotide LAR (Teva, Viatris): Bioequivalent to Sandostatin LAR Depot. May be available through different distribution channels when brand is not, and vice versa. Teva's 20 mg kit experienced backorder through late 2025.
• Generic immediate-release octreotide injection: Available from Avet, Fresenius Kabi, Hikma, Sagent — the most reliably available formulation.

Step 2: Build a Pharmacy Network Before Crises Hit

The most effective preparation is building relationships with multiple specialty pharmacies before your patient is in crisis. Establish working contacts at 2–3 specialty pharmacies in your region. Key national networks that dispense Sandostatin LAR include:

CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), Optum Specialty, BioPlus, McKesson Specialty Health, and hospital-affiliated specialty pharmacies.

When one specialty pharmacy is out, a different distribution network may have stock. Having a pre-established relationship speeds up the transfer.

Step 3: Use medfinder to Locate Available Stock

Rather than having your office staff call pharmacy after pharmacy, direct your patients to medfinder.com/providers for provider tools, or have patients use medfinder directly. medfinder contacts pharmacies near the patient to check which ones can fill the Sandostatin prescription, then texts results to the patient. This removes the phone burden from your staff and gets patients a faster answer.

Step 4: Have a Bridging Protocol Ready

For patients who cannot find their LAR formulation, having a pre-established bridging protocol reduces office workload and delays. Consider the following standard protocol:

• Bridge prescription: Octreotide acetate injection 100–200 mcg SC 2–3 times daily until LAR supply is secured.
• Patient education: Ensure self-injection technique is reviewed. Provide a handout or video resource.
• Monitoring: Schedule a check-in call or telehealth visit 2 weeks after transition to bridge therapy to assess symptom control.
• Return to LAR: When LAR is available, patients on carcinoid or VIPoma indications should continue SC octreotide for at least 2 weeks after the first LAR injection to ensure therapeutic levels are achieved.

Step 5: Prepare Patients to Self-Advocate at Pharmacies

Patients who know what to ask for get results faster. Prepare your patients with these key talking points for specialty pharmacy calls:

• "I'm looking for octreotide for injectable suspension [10/20/30 mg]. Do you have it in stock, or is there a generic (Teva or Viatris) available?"
• "My prescription allows generic substitution — can you check both brand and generic inventory?"
• "Is there a different specialty pharmacy within your network that has it in stock?"

Step 6: Know the Prior Authorization Fast-Track Process

When a shortage requires switching from octreotide to lanreotide, most payers will process the new prior authorization on an expedited timeline if the documentation includes: (1) the FDA drug shortage as clinical context, (2) the patient's indication and current dose, and (3) a statement that the currently prescribed medication is unavailable. Have your authorization team document shortage language explicitly in the PA request.

Create a Patient Handout for Octreotide Shortage Navigation

Consider creating a one-page handout for your octreotide patients that includes:

• medfinder website address and instructions for finding pharmacies with stock
• Novartis Patient Support phone number (1-800-277-2254)
• List of 2–3 specialty pharmacies your office works with and their contact numbers
• Instructions for when to call your office (e.g., "If you can't find it within 5 days, call us for a bridge prescription")
• Symptom warning signs that require urgent evaluation regardless of medication availability

High-Risk Patients: Prioritize Proactive Outreach

Some patients are at greater clinical risk if their octreotide is interrupted. Identify these patients proactively:

• Patients with symptomatic carcinoid syndrome where hormonal bursts can cause flushing crises or carcinoid heart disease progression.
• Acromegaly patients with uncontrolled GH/IGF-1 or at risk for tumor regrowth.
• VIPoma patients — missed doses can cause severe, life-threatening electrolyte disturbances from profound watery diarrhea.

For a deeper dive into the clinical and formulary implications of the shortage, read our complete provider shortage briefing.